메뉴 건너뛰기




Volumn 68, Issue 13, 2008, Pages 1877-1899

Telmisartan/hydrochlorothiazide: A review of its use as fixed-dose combinations in essential hypertension

Author keywords

Adis Drug Evaluations; Hypertension; Telmisartan hydrochlorothiazide, general

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; LITHIUM; MICARDIS HCT; MICARDIS PLUS; NIFEDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

EID: 50249121614     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868130-00010     Document Type: Review
Times cited : (19)

References (68)
  • 2
    • 4644242120 scopus 로고    scopus 로고
    • The burden of adult hypertension in the United States 1999 to 2000: A rising tide
    • Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44 (4): 398-404
    • (2004) Hypertension , vol.44 , Issue.4 , pp. 398-404
    • Fields, L.E.1    Burt, V.L.2    Cutler, J.A.3
  • 3
    • 0038047699 scopus 로고    scopus 로고
    • Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States
    • May 14;
    • Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 May 14; 289 (18): 2363-9
    • (2003) JAMA , vol.289 , Issue.18 , pp. 2363-2369
    • Wolf-Maier, K.1    Cooper, R.S.2    Banegas, J.R.3
  • 4
    • 24944578450 scopus 로고    scopus 로고
    • Epidemiology of uncontrolled hypertension in the United States
    • Sep 13;
    • Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005 Sep 13; 112 (11): 1651-62
    • (2005) Circulation , vol.112 , Issue.11 , pp. 1651-1662
    • Wang, T.J.1    Vasan, R.S.2
  • 5
    • 9144248446 scopus 로고    scopus 로고
    • Hypertension treatment and control in five European countries, Canada, and the United States
    • Jan;
    • Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 Jan; 43 (1): 10-7
    • (2004) Hypertension , vol.43 , Issue.1 , pp. 10-17
    • Wolf-Maier, K.1    Cooper, R.S.2    Kramer, H.3
  • 6
    • 34547615709 scopus 로고    scopus 로고
    • Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
    • Jun;
    • Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-536
    • (2007) Eur Heart J , vol.28 , Issue.12 , pp. 1462-1536
    • Mancia, G.1    De Backer, G.2    Dominiczak, A.3
  • 7
    • 0037079309 scopus 로고    scopus 로고
    • Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies
    • Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
    • (2002) Lancet , vol.360 , pp. 1903-1913
    • Lewington, S.1    Clarke, R.2    Qizilbash, N.3
  • 8
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension Optimal Treatment (HOT) randomized trial
    • Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62
    • (1998) Lancet , vol.351 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3
  • 9
    • 0033982396 scopus 로고    scopus 로고
    • Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification
    • Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539-43
    • (2000) Hypertension , vol.35 , pp. 539-543
    • Ogden, L.G.1    He, J.2    Lydick, E.3
  • 10
    • 0034627183 scopus 로고    scopus 로고
    • Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
    • Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64
    • (2000) Lancet , vol.356 , pp. 1955-1964
    • Neal, B.1    MacMahon, S.2    Chapman, N.3
  • 11
    • 22244471384 scopus 로고    scopus 로고
    • Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: Potential benefits beyond the antihypertensive effect
    • Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs 2005; 5 (3): 171-83
    • (2005) Am J Cardiovasc Drugs , vol.5 , Issue.3 , pp. 171-183
    • Meredith, P.A.1
  • 12
    • 1442299288 scopus 로고    scopus 로고
    • Angiotensin receptor blockers and diuretics as combination therapy: Clinical implications
    • Ram CVS. Angiotensin receptor blockers and diuretics as combination therapy: clinical implications. Am J Hypertens 2004; 17 (3): 277-80
    • (2004) Am J Hypertens , vol.17 , Issue.3 , pp. 277-280
    • Ram, C.V.S.1
  • 13
    • 16644396876 scopus 로고    scopus 로고
    • Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: A review of the factorial-design studies
    • Oct;
    • Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004 Oct; 6 (10): 569-77
    • (2004) J Clin Hypertens (Greenwich) , vol.6 , Issue.10 , pp. 569-577
    • Ram, C.V.1
  • 14
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Dec 18;
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
    • (2002) JAMA , vol.288 , Issue.23 , pp. 2981-2997
  • 15
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Mar 23;
    • Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003
    • (2002) Lancet , vol.359 , Issue.9311 , pp. 995-1003
    • Dahlöf, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 16
    • 2942695964 scopus 로고    scopus 로고
    • Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004 Jun 19; 363 (9426): 2049-51
    • Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004 Jun 19; 363 (9426): 2049-51
  • 19
    • 0141637470 scopus 로고    scopus 로고
    • Telmisartan/hydrochlorothiazide: In the treatment of essential hypertension
    • discussion 2027-8
    • Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63 (19): 2013-26; discussion 2027-8
    • (2003) Drugs , vol.63 , Issue.19 , pp. 2013-2026
    • Fenton, C.1    Keating, G.M.2    Scott, L.J.3
  • 20
    • 31444437343 scopus 로고    scopus 로고
    • Telmisartan: A review of its use in the management of hypertension
    • Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66 (1): 51-83
    • (2006) Drugs , vol.66 , Issue.1 , pp. 51-83
    • Battershill, A.J.1    Scott, L.J.2
  • 21
    • 0346451213 scopus 로고    scopus 로고
    • Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats
    • Jun;
    • Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 2001 Jun; 2 (2): 123-8
    • (2001) J Renin Angiotensin Aldosterone Syst , vol.2 , Issue.2 , pp. 123-128
    • Wienen, W.1    Schierok, H.J.2
  • 22
    • 18844413772 scopus 로고    scopus 로고
    • Effect of telmisartan/ hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation
    • May;
    • Fogari R, Preti P, Zoppi A, et al. Effect of telmisartan/ hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am J Hypertens 2005 May; 18 (5 Pt 1): 577-83
    • (2005) Am J Hypertens , vol.18 , Issue.5 PART 1 , pp. 577-583
    • Fogari, R.1    Preti, P.2    Zoppi, A.3
  • 23
    • 33744909553 scopus 로고    scopus 로고
    • Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients
    • Mar;
    • Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006 Mar; 20 (3): 177-85
    • (2006) J Hum Hypertens , vol.20 , Issue.3 , pp. 177-185
    • Fogari, R.1    Mugellini, A.2    Zoppi, A.3
  • 24
    • 0033747596 scopus 로고    scopus 로고
    • Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
    • Dec;
    • Yong CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1323-30
    • (2000) J Clin Pharmacol , vol.40 , Issue.12 PART 1 , pp. 1323-1330
    • Yong, C.L.1    Dias, V.C.2    Stangier, J.3
  • 25
    • 0035852724 scopus 로고    scopus 로고
    • Angiotensin II type 1 receptor blockers
    • Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-12
    • (2001) Circulation , vol.103 , pp. 904-912
    • Burnier, M.1
  • 26
    • 0034088314 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
    • Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 Suppl. 1: S73-86
    • (2000) J Hum Hypertens , vol.14 , Issue.SUPPL. 1
    • Israili, Z.H.1
  • 27
    • 50249115474 scopus 로고    scopus 로고
    • U.S. Pharmacopeia. 2008 USP Dictionary of USAN and International Drug Names. Rockville (MD): U.S. Pharmacopeia, 2008
    • U.S. Pharmacopeia. 2008 USP Dictionary of USAN and International Drug Names. Rockville (MD): U.S. Pharmacopeia, 2008
  • 28
    • 0033840660 scopus 로고    scopus 로고
    • Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
    • Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28 (4): 149-67
    • (2000) J Int Med Res , vol.28 , Issue.4 , pp. 149-167
    • Stangier, J.1    Su, C.A.2    Roth, W.3
  • 29
    • 0021360689 scopus 로고
    • Bioavailability of hydrochlorothiazide from tablets and suspensions
    • Mar;
    • Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984 Mar; 73 (3): 359-61
    • (1984) J Pharm Sci , vol.73 , Issue.3 , pp. 359-361
    • Patel, R.B.1    Patel, U.R.2    Rogge, M.C.3
  • 30
    • 0017693612 scopus 로고
    • Pharmacokinetics of hydrochlorothiazide in man
    • Dec 2;
    • Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
    • (1977) Eur J Clin Pharmacol , vol.12 , Issue.4 , pp. 297-303
    • Beermann, B.1    Groschinsky-Grind, M.2
  • 31
    • 0033740069 scopus 로고    scopus 로고
    • Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers
    • Dec;
    • Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1312-22
    • (2000) J Clin Pharmacol , vol.40 , Issue.12 PART 1 , pp. 1312-1322
    • Stangier, J.1    Schmid, J.2    Turck, D.3
  • 32
    • 0020549612 scopus 로고
    • Pharmacokinetics of hydrochlorothiazide in relation to renal function
    • Niemeyer C, Hasenfuss G, Wais U, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 1983; 24 (5): 661-5
    • (1983) Eur J Clin Pharmacol , vol.24 , Issue.5 , pp. 661-665
    • Niemeyer, C.1    Hasenfuss, G.2    Wais, U.3
  • 33
    • 0033748477 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
    • Dec;
    • Stangier J, Su CA, Schöndorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1355-64
    • (2000) J Clin Pharmacol , vol.40 , Issue.12 PART 1 , pp. 1355-1364
    • Stangier, J.1    Su, C.A.2    Schöndorfer, G.3
  • 34
    • 0035149097 scopus 로고    scopus 로고
    • Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan mono-therapy
    • Nov;
    • Lacourcière Y, Tytus R, O'Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan mono-therapy. J Hum Hypertens 2001 Nov; 15 (11): 763-70
    • (2001) J Hum Hypertens , vol.15 , Issue.11 , pp. 763-770
    • Lacourcière, Y.1    Tytus, R.2    O'Keefe, D.3
  • 35
    • 0036511319 scopus 로고    scopus 로고
    • Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension
    • Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002; 9 (2): 111-7
    • (2002) Am J Ther , vol.9 , Issue.2 , pp. 111-117
    • Lacourcière, Y.1    Martin, K.2
  • 36
    • 0034984319 scopus 로고    scopus 로고
    • Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
    • Jun;
    • McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001 Jun; 23 (6): 833-50
    • (2001) Clin Ther , vol.23 , Issue.6 , pp. 833-850
    • McGill, J.B.1    Reilly, P.A.2
  • 37
    • 0035163816 scopus 로고    scopus 로고
    • Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension
    • Jan;
    • McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001 Jan; 24 (1): 66-72
    • (2001) Clin Cardiol , vol.24 , Issue.1 , pp. 66-72
    • McGill, J.B.1    Reilly, P.A.2
  • 38
    • 0036429458 scopus 로고    scopus 로고
    • Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications
    • Neutel JM, Klein C, Meinicke TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11 (5): 302-9
    • (2002) Blood Press , vol.11 , Issue.5 , pp. 302-309
    • Neutel, J.M.1    Klein, C.2    Meinicke, T.W.3
  • 39
    • 0036300934 scopus 로고    scopus 로고
    • Long-term exposure to telmisartan as monotherapy or combination therapy: Efficacy and safety
    • Freytag F, Holwerda NJ, Karlberg BE, et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11 (3): 173-81
    • (2002) Blood Press , vol.11 , Issue.3 , pp. 173-181
    • Freytag, F.1    Holwerda, N.J.2    Karlberg, B.E.3
  • 40
    • 33645081264 scopus 로고    scopus 로고
    • Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    • Oct;, quiz 596-7
    • Bakris GL, Smith DH, Giles TD, et al. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich) 2005 Oct; 7 (10): 587-95; quiz 596-7
    • (2005) J Clin Hypertens (Greenwich) , vol.7 , Issue.10 , pp. 587-595
    • Bakris, G.L.1    Smith, D.H.2    Giles, T.D.3
  • 41
    • 29144535666 scopus 로고    scopus 로고
    • Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
    • Jan;
    • White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 2006 Jan; 151 (1): 176-84
    • (2006) Am Heart J , vol.151 , Issue.1 , pp. 176-184
    • White, W.B.1    Giles, T.2    Bakris, G.L.3
  • 42
    • 33747489669 scopus 로고    scopus 로고
    • An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    • Apr;, quiz 251-2
    • Weber MA, White WB, Giles TD, et al. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens 2006 Apr; 8 (4): 241-50; quiz 251-2
    • (2006) J Clin Hypertens , vol.8 , Issue.4 , pp. 241-250
    • Weber, M.A.1    White, W.B.2    Giles, T.D.3
  • 43
    • 50249105081 scopus 로고    scopus 로고
    • Telmisartan improves home blood pressure control during the critical morning hours: Results from a post-marketing study (SURGE-2) [abstract no. P-426]
    • May;
    • Redon J, Bilo G, Parati G. Telmisartan improves home blood pressure control during the critical morning hours: results from a post-marketing study (SURGE-2) [abstract no. P-426]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): A177-8
    • (2007) J Clin Hypertens , vol.9 , Issue.5 SUPPL. A
    • Redon, J.1    Bilo, G.2    Parati, G.3
  • 44
    • 50249095539 scopus 로고    scopus 로고
    • Telmisartan improves ambulatory blood pressure control over 24 hours and in the morning: Results from a practice-based study (SURGE-2) [abstract no. P-420]
    • May;
    • Parati G, Bilo G, Redon J. Telmisartan improves ambulatory blood pressure control over 24 hours and in the morning: results from a practice-based study (SURGE-2) [abstract no. P-420]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): A175
    • (2007) J Clin Hypertens , vol.9 , Issue.5 SUPPL. A
    • Parati, G.1    Bilo, G.2    Redon, J.3
  • 45
    • 34547100641 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension
    • Sep;
    • White WB, Punzi HA, Murwin D, et al. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006 Sep; 8 (9): 626-33
    • (2006) J Clin Hypertens (Greenwich) , vol.8 , Issue.9 , pp. 626-633
    • White, W.B.1    Punzi, H.A.2    Murwin, D.3
  • 46
    • 38349042145 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide: A large, confirmatory trial
    • Feb;
    • White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008 Feb; 13 (1): 21-7
    • (2008) Blood Press Monit , vol.13 , Issue.1 , pp. 21-27
    • White, W.B.1    Murwin, D.2    Chrysant, S.G.3
  • 47
    • 36349011426 scopus 로고    scopus 로고
    • Telmisartan/ hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study
    • Epub Oct 2
    • Sharma AM, Davidson J, Koval S, et al. Telmisartan/ hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. Epub 2007 Oct 2
    • (2007) Cardiovasc Diabetol
    • Sharma, A.M.1    Davidson, J.2    Koval, S.3
  • 48
    • 25844466623 scopus 로고    scopus 로고
    • Telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension
    • Jul;
    • Neutel JM, Littlejohn TW, Chrysant SG, et al. Telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005 Jul; 28 (7): 555-63
    • (2005) Hypertens Res , vol.28 , Issue.7 , pp. 555-563
    • Neutel, J.M.1    Littlejohn, T.W.2    Chrysant, S.G.3
  • 49
    • 0038541642 scopus 로고    scopus 로고
    • Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension
    • May;
    • Lacourcière Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003 May; 57 (4): 237-79
    • (2003) Int J Clin Pract , vol.57 , Issue.4 , pp. 237-279
    • Lacourcière, Y.1    Gil-Extremera, B.2    Mueller, O.3
  • 50
    • 29144442424 scopus 로고    scopus 로고
    • Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005 Nov; 27 (11): 1795-805
    • Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005 Nov; 27 (11): 1795-805
  • 51
    • 41249095681 scopus 로고    scopus 로고
    • Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: A prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study
    • Feb;
    • Fogari R, Zoppi A, Mugellini A, et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr Ther Res Clin Exp 2008 Feb; 69 (1): 1-15
    • (2008) Curr Ther Res Clin Exp , vol.69 , Issue.1 , pp. 1-15
    • Fogari, R.1    Zoppi, A.2    Mugellini, A.3
  • 52
    • 33750976110 scopus 로고    scopus 로고
    • Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: Results from a large ambulatory blood pressure monitoring study
    • Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15 (3): 151-60
    • (2006) Am J Geriatr Cardiol , vol.15 , Issue.3 , pp. 151-160
    • Neldam, S.1    Edwards, C.2
  • 53
    • 50249090877 scopus 로고    scopus 로고
    • Efficacy and safety of a fixed-dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with uncontrolled hypertension [abstract no. P12.332]
    • Neldam S, Edwards C. Efficacy and safety of a fixed-dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with uncontrolled hypertension [abstract no. P12.332]. J Hypertens 2006; 25 Suppl. 2: S114
    • (2006) J Hypertens , vol.25 , Issue.SUPPL. 2
    • Neldam, S.1    Edwards, C.2
  • 54
    • 50249185492 scopus 로고    scopus 로고
    • Efficacy and safety of telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) fixed-dose combination (FDC), alone or with other antihypertensive medications, during open-label long-term treatment [abstract no. P-286]
    • May;
    • Neldam S, Edwards C. Efficacy and safety of telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) fixed-dose combination (FDC), alone or with other antihypertensive medications, during open-label long-term treatment [abstract no. P-286]. J Clin Hypertens 2008 May; 10 (5 Suppl. A): A123
    • (2008) J Clin Hypertens , vol.10 , Issue.5 SUPPL. A
    • Neldam, S.1    Edwards, C.2
  • 55
    • 74249103427 scopus 로고    scopus 로고
    • The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies
    • Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 2008; 17 Suppl. 1: 32-40
    • (2008) Blood Press , vol.17 , Issue.SUPPL. 1 , pp. 32-40
    • Schumacher, H.1    Mancia, G.2
  • 57
    • 33744966030 scopus 로고    scopus 로고
    • Major congenital malformations after first-trimester exposure to ACE inhibitors
    • Jun 8;
    • Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006 Jun 8; 354 (23): 2443-51
    • (2006) N Engl J Med , vol.354 , Issue.23 , pp. 2443-2451
    • Cooper, W.O.1    Hernandez-Diaz, S.2    Arbogast, P.G.3
  • 58
    • 33748896939 scopus 로고    scopus 로고
    • ACE inhibitors and major congenital malformations [letter]
    • Sep 21;
    • Sealey JE, Itskovitz-Eldor J. ACE inhibitors and major congenital malformations [letter]. N Engl J Med 2006 Sep 21; 355 (12): 1280-1
    • (2006) N Engl J Med , vol.355 , Issue.12 , pp. 1280-1281
    • Sealey, J.E.1    Itskovitz-Eldor, J.2
  • 59
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
    • Sep 10;
    • Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10; 366: 895-906
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlöf, B.1    Sever, P.S.2    Poulter, N.R.3
  • 60
    • 24644503688 scopus 로고    scopus 로고
    • Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
    • Sep 10;
    • Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005 Sep 10; 366 (9489): 907-13
    • (2005) Lancet , vol.366 , Issue.9489 , pp. 907-913
    • Poulter, N.R.1    Wedel, H.2    Dahlöf, B.3
  • 61
    • 57649154812 scopus 로고    scopus 로고
    • Avoiding Cardiovascular Events Through COMbination Therapy in Patients LIving with Systolic Hypertension, the early termination of the ACCOMPLISH trial for efficacy [abstract no. 407-2]
    • Session of the American College of Cardiology; Mar 30-Apr 1; Chicago IL
    • Jamerson KA, Weber MA, Bakris GL, et al. Avoiding Cardiovascular Events Through COMbination Therapy in Patients LIving with Systolic Hypertension, the early termination of the ACCOMPLISH trial for efficacy [abstract no. 407-2]. 57th Annual Scientific Session of the American College of Cardiology; 2008 Mar 30-Apr 1; Chicago (IL)
    • (2008) 57th Annual Scientific
    • Jamerson, K.A.1    Weber, M.A.2    Bakris, G.L.3
  • 62
    • 50249173255 scopus 로고    scopus 로고
    • O'Riordan M. ACCOMPLISH: ACE inhibitor plus calcium-channel blocker best for reducing clinical events in hypertensive patients [media release; online]. Available from URL: http://www.medscape.com/viewarticle/572304 [Accessed 2008 May 27]
    • O'Riordan M. ACCOMPLISH: ACE inhibitor plus calcium-channel blocker best for reducing clinical events in hypertensive patients [media release; online]. Available from URL: http://www.medscape.com/viewarticle/572304 [Accessed 2008 May 27]
  • 63
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • The ONTARGET Investigators, Apr 10;
    • The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-58
    • (2008) N Engl J Med , vol.358 , Issue.15 , pp. 1547-1558
  • 64
    • 42549125725 scopus 로고    scopus 로고
    • Mancia G, Jakobsen A, Heroys J, et al. Cardiac and vascular protection: the potential of ONTARGET. Medscape J Med 2008 Mar 26; 10 Suppl.: S7
    • Mancia G, Jakobsen A, Heroys J, et al. Cardiac and vascular protection: the potential of ONTARGET. Medscape J Med 2008 Mar 26; 10 Suppl.: S7
  • 66
    • 33645079955 scopus 로고    scopus 로고
    • The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial
    • Oct;
    • Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens 2005 Oct; 7 (10): 578-86
    • (2005) J Clin Hypertens , vol.7 , Issue.10 , pp. 578-586
    • Neutel, J.M.1    Saunders, E.2    Bakris, G.L.3
  • 67
    • 0042471622 scopus 로고    scopus 로고
    • Relevance of blood pressure variation in the circadian onset of cardiovascular events
    • White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 Suppl. 6: S9-15
    • (2003) J Hypertens , vol.21 , Issue.SUPPL. 6
    • White, W.B.1
  • 68
    • 0028927046 scopus 로고
    • Implications of small reductions in diastolic blood pressure for primary prevention
    • Apr 10;
    • Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995 Apr 10; 155 (7): 701-9
    • (1995) Arch Intern Med , vol.155 , Issue.7 , pp. 701-709
    • Cook, N.R.1    Cohen, J.2    Hebert, P.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.